Vitrafy Life Sciences Cash Flow Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Net Income	-14.15	-32.71	-10.43	-7.81	-7.66
Depreciation & Amortization	0.14	0.15	0.21	0.26	0.19
Other Amortization	-	-	2.03	0.81	-
Stock-Based Compensation	2.08	2.08	0.19	0.36	0.11
Other Operating Activities	-2.28	18.9	1.78	0.65	3.03
Change in Accounts Receivable	-0.45	-0.45	-0.05	-0.02	-0.02
Change in Accounts Payable	0.37	0.37	-0.23	0.31	-0.11
Change in Unearned Revenue	1.43	1.43	-	-	-
Change in Other Net Operating Assets	1.43	1.43	-0.3	0.49	-1.42
Operating Cash Flow	-11.44	-8.8	-6.79	-4.96	-5.87
Capital Expenditures	-	-0	-0.01	-0.09	-0.49
Investment in Securities	9.93	-10.08	-	-	-
Investing Cash Flow	9.93	-10.08	-0.01	-0.09	-0.49
Short-Term Debt Issued	-	-	12.55	6.31	-
Total Debt Issued	-	-	12.55	6.31	-
Short-Term Debt Repaid	-	-	-0.55	-0.4	-
Long-Term Debt Repaid	-	-0.08	-0.13	-0.1	-0.06
Total Debt Repaid	-0.09	-0.08	-0.68	-0.5	-0.06
Net Debt Issued (Repaid)	-0.09	-0.08	11.87	5.82	-0.06
Issuance of Common Stock	-	35.32	0.27	0.09	-
Other Financing Activities	-0.03	-3.25	-0.64	-0.1	-
Financing Cash Flow	-0.12	31.99	11.5	5.8	-0.06
Net Cash Flow	-1.73	13.11	4.69	0.76	-6.42
Free Cash Flow	-11.44	-8.8	-6.8	-5.05	-6.36
Free Cash Flow Margin	-488.21%	-840.18%	-330.33%	-245.44%	-348.32%
Free Cash Flow Per Share	-0.18	-0.20	-2.22	-1.71	-2.17
Levered Free Cash Flow	-7.51	-29.04	-9.1	0.73	-
Unlevered Free Cash Flow	-7.5	-24.98	-2.58	3.86	-
Change in Working Capital	2.78	2.78	-0.58	0.78	-1.55

Source: S&P Global Market Intelligence. Standard template. Financial Sources.